BeOne Medicines (FRA:49BA) Cyclically Adjusted Book per Share: €29.22 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:49BA BeOne Medicines Ltd FRA:49BA
80 GF Score
Price €318.00
GF Value €316.58
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is BeOne Medicines Cyclically Adjusted Book per Share?

BeOne Medicines FRA:49BA +0.63% 80 Cyclically Adjusted Book per Share is €29.22 as of Jun. 2026. GuruFocus rates FRA:49BA with a GF Score™ of 80/100 and a GF Value™ of €316.58 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

BeOne Medicines's adjusted book value per share for the three months ended in Jun. 2026 was €39.724. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €29.22 for the trailing ten years ended in Jun. 2026.

During the past 12 months, BeOne Medicines's average Cyclically Adjusted Book Growth Rate was 13.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-08-27), BeOne Medicines's current stock price is €318.00. BeOne Medicines's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was €29.22. BeOne Medicines's Cyclically Adjusted PB Ratio of today is 10.88.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of BeOne Medicines was 11.92. The lowest was 4.78. And the median was 8.73.


BeOne Medicines  (FRA:49BA) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

BeOne Medicines's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=318.00/29.22
=10.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of BeOne Medicines was 11.92. The lowest was 4.78. And the median was 8.73.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


BeOne Medicines Cyclically Adjusted Book per Share Related Terms


BeOne Medicines Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for BeOne Medicines's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeOne Medicines Cyclically Adjusted Book per Share Chart

BeOne Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 26.86 26.85

BeOne Medicines Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.73 25.76 26.85 27.34 29.22

FRA:49BA vs ALNY, RVMD, RPRX: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, BeOne Medicines's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BeOne Medicines Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeOne Medicines's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where BeOne Medicines's Cyclically Adjusted PB Ratio falls into.


FRA:49BA
80GF Score
BeOne Medicines Ltd FRA:49BA
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BeOne Medicines Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BeOne Medicines's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=39.724/108.5600*108.5600
=39.724

Current CPI (Jun. 2026) = 108.5600.

BeOne Medicines Quarterly Data

Book Value per Share CPI Adj_Book
201609 5.077 99.604 5.533
201612 8.431 99.380 9.210
201703 7.229 100.040 7.845
201706 5.702 100.285 6.172
201709 13.873 100.254 15.022
201712 12.427 100.213 13.462
201803 20.279 100.836 21.832
201806 19.244 101.435 20.596
201809 28.468 101.246 30.525
201812 25.656 100.906 27.602
201903 23.833 101.571 25.473
201906 22.790 102.044 24.245
201909 19.238 101.396 20.597
201912 14.049 101.063 15.091
202003 32.824 101.048 35.264
202006 28.847 100.743 31.085
202009 40.004 100.585 43.176
202012 34.721 100.241 37.603
202103 36.514 100.800 39.325
202106 32.308 101.352 34.606
202109 30.576 101.533 32.692
202112 52.858 101.776 56.382
202203 52.047 103.205 54.748
202206 48.317 104.783 50.059
202209 45.288 104.835 46.897
202212 39.666 104.666 41.142
202303 37.044 106.245 37.851
202306 33.235 106.576 33.854
202309 33.884 106.570 34.517
202312 31.127 106.461 31.741
202403 29.587 107.355 29.919
202406 29.555 107.991 29.711
202409 29.154 107.468 29.450
202412 29.873 107.128 30.272
202503 29.988 107.722 30.221
202506 29.779 108.075 29.913
202509 31.804 107.710 32.055
202512 33.598 107.200 34.024
202603 37.043 108.060 37.214
202606 39.724 108.560 39.724

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €29.22 mean?
BeOne Medicines (FRA:49BA) has a Cyclically Adjusted Book per Share of €29.22 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on BeOne Medicines and its competitors.
Is BeOne Medicines' Cyclically Adjusted Book per Share too high?
BeOne Medicines' current Cyclically Adjusted Book per Share is €29.22. Overall, BeOne Medicines has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Cyclically Adjusted Book per Share compare to ALNY and RVMD?
BeOne Medicines' Cyclically Adjusted Book per Share of €29.22 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on BeOne Medicines and its competitors. BeOne Medicines's current Cyclically Adjusted Book per Share is €29.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (FRA:49BA) is currently considered Fairly Valued. The stock's GF Value™ is €316.58, compared to a current price of €318.00 — trading 0.4% above its estimated fair value. The current Cyclically Adjusted Book per Share is €29.22. BeOne Medicines' overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For BeOne Medicines (FRA:49BA), the current Cyclically Adjusted Book per Share is €29.22 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BeOne Medicines (FRA:49BA) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be overvalued. The current stock price of €318.00 is trading 0.4% above its estimated GF Value™ of €316.58. GuruFocus considers BeOne Medicines to be Fairly Valued.

Key valuation signals for FRA:49BA:

  • Cyclically Adjusted Book per Share: €29.22
  • GF Value™: €316.58 vs. price of €318.00 (0.4% above fair value)
  • GF Score™: 80/100 with 5 warning signs

No single metric tells the full story. See the FRA:49BA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BeOne Medicines Business Description

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
80GF Score

Get the complete analysis for FRA:49BA

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€318.00
Price
€316.58
GF Value